VALUE IN HEALTH REGIONAL ISSUES 10C (2016) Available online at journal homepage:
|
|
- Amice Powell
- 5 years ago
- Views:
Transcription
1 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) Available online at journal homepage: Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and rostate-specific Antigen Kinetics in Localized rostate Cancer Makbule Tambas, MD 1, Fulya Agaoglu, MD 1, *, Ayca Iribas, MD 1, Murat Guveli, MD 1, Yavuz Dizdar, MD 1, Murat Okutan, hd 2, Dilek Sahin, MD 3, Nuri Tenekeci, MD 3, Emin Darendeliler, MD 1 1 Department of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey; 2 Department of Medical hysics, Institute of Oncology, University of Istanbul, Istanbul, Turkey; 3 Department of Radiology, Institute of Oncology, University of Istanbul, Istanbul, Turkey ABSTRACT Objectives: To compare conventionally fractionationed volumetric arc therapy (VMAT) and hypofractionated stereotactic body radiotherapy (SBRT) modalities in terms of prostate-specific antigen (SA) kinetics, toxicity, and quality of life (QOL) in patients with localized prostate cancer. Methods: atients received radical radiotherapy as either 33.5 Gy/5 fr for SBRT or 75.6 Gy/35 fr for VMAT. International rostate Symptom Score (ISS) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire rostate Cancer Module (QLQ-R25) forms were used to assess QOL. Results: Of the 48 patients(28 in SBRT and 20 in VMAT)includedinthestudy,40(20inSBRTand20inVMAT)were evaluated for QOL status. SA control rate was 100% and SA nadir value was 0.5 ng/dl in both arms during the median follow-up period of 23 months. The magnitude of SA bounce was higher in the SBRT arm than in the VMAT arm ( ¼ 0.01). The SA decline rate in the VMAT arm was higher than in the SBRT arm ( ¼ 0.028). Three (10.7%) patients treated with SBRT who had a history of transurethral resection of the prostate (TUR) experienced grade 3 urinary toxicity. No significant difference was observed concerning sexual activity and sexual functioning scores, whereas scores at 10.5 and 13.5 months were decreased in both arms. The SBRT and VMAT arms had similar urinary incontinence, bowel symptoms, and ISS obstruction scores. The magnitude of increase in ISS scores at treatment completion was higher in the VMAT arm than in the SBRT arm ( ¼ 0.046). The decrease in hormonal symptom scores at 4.5, 10.5, and 13.5 months was higher in the VMAT arm than in the SBRT arm ( ¼ 0.007, 0.027, and 0.021, respectively). Conclusions: Both treatment modalities had similar effectiveness and provided acceptable outcomes in terms of toxicity and QOL. Grade 3 urinary toxicities might be eliminated with careful patient selection for SBRT. Keywords: prostate cancer, quality of life, SBRT, toxicity, VMAT. Copyright & 2016, International Society for harmacoeconomics and Outcomes Research (ISOR). ublished by Elsevier Inc. Introduction rostate cancer is the most common type of cancer in men. In 2014, some 233,000 patients were newly diagnosed as having prostate cancer, which constitutes 27% of new cancer cases in men [1]. Nevertheless, deaths due to prostate cancer were reduced by 4.1% per year between 1994 and 2001; 29,480 deaths occurred because of prostate cancer in 2014 [1]. This low mortality rate can be explained by the awareness of early detection in the community and increased disease control through effective treatment modalities. Nevertheless, early diagnosis and treatment of prostate cancer that does not threaten life expectancy may result in unnecessary adverse effects, deterioration in quality of life (QOL), and an increase in health care costs. Thus, the determination of treatment indication and treatment modalities to be applied is one of the most important issues in prostate cancer management. There are many different options for the treatment of localized prostate cancer, including active surveillance, surgery, brachytherapy, cryotherapy, and high-intensity focused ultrasound, but each has its unique adverse effects. External beam radiotherapy (RT) is another treatment modality that increased biochemical control rates in patients with prostate cancer [2,3]. The results of dose escalation studies in the 1990s revealed that increased RT doses led to higher prostate-specific antigen (SA) control rates, as well as increased toxicity, mainly in the form of rectal bleeding [2 4]. The therapeutic index has increased considerably through the ability of highly conformal dose constraints for normal tissue provided by modern technology. Intensity-modulated radiation Conflict of interest: The authors have indicated that they have no conflicts of interest with regard to the content of this article. *Address correspondence to: Fulya Agaoglu, Department of Radiation Oncology, Institute of Oncology, Istanbul University, Capa 34390, Istanbul, Turkey. agaoglufulya@gmail.com $36.00 see front matter Copyright & 2016, International Society for harmacoeconomics and Outcomes Research (ISOR). ublished by Elsevier Inc.
2 92 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) therapy (IMRT) led to decreased toxicity rates while increasing local control rates [5,6]. In addition, volumetric arc therapy (VMAT) was shown to provide better outcomes than other IMRT techniques in terms of target organ coverage, conformity index, homogeneity index, the dose received by organs at risk, monitor unit (MU) delivered, and acute toxicities in many dosimetric studies [7 9]. Therefore, the use of VMAT has become widespread instead of other IMRT techniques in centers with available infrastructure for the arc therapy. The therapeutic index is theoretically expected to be increased with hypofractionated regimens because the α/β ratio of prostate cancer cells is approximately 1.5. On the basis of this hypothesis, many studies were conducted that investigated the efficacy of the linear accelerator based or robotic-based stereotactic body radiotherapy (SBRT). The results of these studies involving 1100 patients with localized prostate cancer who received a median dose of Gy (range, Gy)/4 to 5 fr for noncoplanar robotic SBRT were reported in the SBRT consortium. Five-year biochemical relapse-free survivals for low-, medium-, and high-risk patients were detected as 95%, 84%, and 81%, respectively [10]. Both SBRT and VMAT treatments have unique theoretical advantages. Nevertheless, a much shorter total treatment time in SBRT treatment compared with VMAT treatment is one of the greatest advantages of SBRT for treatment centers and patients. Although the efficacy of both treatments was illustrated in several studies, the follow-up period of SBRT treatment is not as long as that of fractionationed regimens, which makes longterm follow-up periods important regarding adverse effects [10]. Nowadays, the satisfaction and QOL of patients have become as important as the success of treatment. Treatment toxicity and QOL of patients are decisive factors in choosing the treatment modality to be administered among different treatment options for prostate cancer, which has a high control ratio and long survival expectancy. Therefore, for the first time in the literature, we intended to compare conventionally fractionationed VMAT with hypofractionated SBRT in terms of SA kinetics, treatmentrelated adverse effects, and QOL inpatients with localized prostate cancer. Methods atients diagnosed with localized prostate cancer who were admitted to our institution between March 2010 and December 2013 and met the study criteria were included in this prospective study. The terms of the study were approved by the institutional ethics committee. rocedures were conducted in accordance with the Declaration of Helsinki of 1975, as revised in The informed consent from patients was taken before treatment. Forty-eight patients were included in the study (28 in SBRT and 20 in VMAT). In addition, of these 48 patients, 40 (20 in SBRT and 20 in VMAT) were evaluated for their QOL status with appropriate forms and questionnaires. The remaining 8 patients in the SBRT arm were excluded from the QOL assessment because of incompliance while responding to the questions in the QOL forms. Androgen deprivation therapy (ADT) was administered as a monotherapy including bicalutamide 50 mg (1 1) for 10 days followed by leuprolide acetate at 3-month intervals. RT treatment planning was scheduled after 3 months following ADT initiation. Two weeks before RT simulation, three to four gold fiducial markers were inserted transrectally by an experienced radiologist. The fiducials were placed in the apex, lateral zone, and base of the prostate. Contrast-enhanced planning computed tomography with 1-mm slice thickness was done using the hilips Brilliance (hilips Switzerland, Amsterdam, the Netherlands) device. RT Treatment lanning The prostate gland, seminal vesicles, rectum, bladder, penile bulb, femoral heads, and fiducials were contoured. A clinical target volume (CTV) was created with no margin to the prostate and in very low risk and low-risk patients, whereas the CTV included the prostate and the 1-cm proximal part of the vesicula seminalis in other patients without margin. A 3-mm margin posteriorly and a 5- mm margin from other directions were given to the CTV to create a planning target volume. Conturing was performed using a Varian Eclipse TS version 8.9 (Varian Medical Systems, alo Alto, CA) planning system for VMAT planning. Double full arcs with to gantry angles counterclockwise and to gantry angles clockwise were planned using 6-MV photon energy. RT was performed using a Varian DHX RapidArc (Varian Medical Systems, alo Alto, CA) device. Delineation was performed using the Multilan MD Suite planning system (Accuray, Sunnyvale, CA, USA) for SBRT planning. RT was administered with a (Accuray, Sunnyvale, CA, USA) device to patients in the SBRT arm. atients received radical RT with doseschedulesofeither33.5gy/5frforsbrtor75.6gy/35frfor VMAT, the biological 2-Gy equivalent dose for both of which was 78 Gy/39 fr. RT Toxicity Assessments Acute and late toxicity of RT were evaluated on the basis of Common Terminology Criteria for Adverse Events version 4. QOL Assessments The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire rostate Cancer Module (QLQ-R25) module questionnaire and the International rostate Symptom Score (ISS) form were used to assess the QOL of patients before and at the end of treatment, 1.5 months posttreatment, and during subsequent control periods at 3-month intervals. The EORTC QLQ-R25 module consists of parameters to evaluate the functionality and symptoms of patients. All scales were scored from 0 to 100. Higher scale scores indicate a greater level of response. Higher scores for functioning scales show higher/healthier levels of functionality, but higher symptom scale scores indicate greater symptoms/problems [11]. The ISS comprises eight questions (seven symptom questions and one QOL question) to screen symptoms of the lower genitourinary track. The seven symptom questions are related to the following: 1) feeling of incomplete bladder emptying, 2) frequency, 3) intermittency, 4) urgency, 5) weak stream, 6) straining, and 7) nocturia. Each could be scored from 1 to 5 for a maximum of 35 points. The eighth question on QOL is assigned a score of 1 to 6. The ISS obstruction (ISS-O) score is the sum of ISS questions 1, 3, 5, and 6, which show the degree of symptoms related to the obstruction of the urinary tract. The QOL measures were recorded face to face before seeing the physician, and the same order was followed each time. Figure 1 shows the medical interventions and the timing of the administration of QOL assessments. Statistical Analysis For descriptive statistics of the data, mean, SD, median, minimum, maximum, frequency, and ratio values were used. The distribution of variables was measured using the Kolmogorov- Smirnov test. The independent samples t test and the Mann- Whitney U test were used for the analysis of quantitative data. The paired Wilcoxon test was used to analyze repeated
3 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) measures. The chi-square test was used to analyze qualitative data. The SSS version 22.0 software (SSS Inc., Chicago, IL., USA) was used for statistical analysis. Results The median follow-up period was 23 months. There was no difference between the SBRT and VMAT arms in terms of median age (38.5 years [range years] vs years [range years]; ¼ 0.11), rates of patients undergoing ADT (32% vs. 55%; ¼ 0.11), and disease risk group according to the National Comprehensive Cancer Network guidelines classification ( ¼ 0.84). The numbers of very low, low-, medium-, and highrisk patients were 2 (7.1%), 10 (35.7%), 15 (53.6%), and 1 (3.6%) in the SBRT group and 4 (20%), 4 (20%), 10 (50%), and 2 (10%) in the VMAT group, respectively. The demographic characteristics of patients at baseline are presented in Table 1. Fig. 1 The medical interventions and the timing of administration of QOL assessments. QOL, quality of life; RT, radiotherapy; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy. SA Kinetics No significant differences were detected between the SBRT and VMAT arms in terms of SA values pre-rt ( vs ng/ml; ¼ 0.61) and 4.5 months ( vs ng/ml; ¼ 0.10) and 13.5 months ( vs ng/ml; ¼ 0.81) after RT. Nevertheless, SA values in the SBRT arm 1.5 months ( vs ng/ml; ¼ 0.04), 7.5 months ( vs ng/ml; Table 1 The demographic characteristics of patients at baseline. Characteristic SBRT VMAT Mean SD/n (%) Median (min. max.) Mean SD/n (%) Median (min. max.) Age (y) (57 82) (52 79) Alcohol consumption No 21 (75) 14 (70) Yes 7 (25) 6 (30) Smoking No 13 (46.4) 5 (25) Yes 15 (53.6) 15 (75) Hypertension No 12 (43) 8 (40) Yes 16 (57) 12 (60) Coronary artery disease No 18 (64.3) 16 (80) Yes 10 (35.7) 4 (20) Diabetes mellitus No 25 (89.3) 14 (70) Yes 3 (10.7) 6 (30) Gastrointestinal system disease No 28 (100) 20 (100) Yes 0 (0.0) 0 (0) ADT No 19 (68) 9 (45) Yes 9 (32) 11 (55) Risk classification Very low 2 (7.1) 4 (20) Low 10 (35.7) 4 (20) Intermediate 15 (53.6) 10 (50) High 1 (3.6) 2 (10) Note. Independent samples t test, Mann-Whitney U test, and χ 2 test were used. ADT, androgen deprivation therapy; max., maximum; min., minimum; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy.
4 94 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) ¼ 0.02) compared with pre-rt scores in the SBRT arm. Nevertheless, a significant increase in the total ISS score at the end of RT ( ¼ 0.02) and significant reductions in both ISS and ISS-O scores at 13.5 months ( ¼ 0.04 and ¼ 0.02) were observed in the VMAT arm (Table 3). Fig. 2 Changes in SA values over time in the SBRT and VMAT groups. SA, prostate-specific antigen; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy. ¼ 0.02), and 10.5 months ( vs ng/ml; ¼ 0.04) after RT were found to be significantly higher than those in the VMAT arm (Fig. 2). SA control, SA nadir, and SA bounce According to the hoenix criteria, which accept SA relapse as 2 ng/ml or more increase than SA nadir (SAn), no SA recurrence was observed during follow-up and the SA control rate was 100%. The SAn value ( vs ng/ml; ¼ 0.2), SAn time value ( vs months; ¼ 0.08), the first SA bounce (SAb) frequency (57% vs. 50%; ¼ 0.6), the time when the first SAb was observed ( vs months; ¼ 0.4), the second incidence of SAb (35.7% vs. 25%; ¼ 0.4), the time when the second SAb was seen ( vs months; ¼ 0.2), the magnitude of the second SAb ( vs ng/ml; ¼ 0.6), and the total number of SAb detected ( vs ; ¼ 0.5) did not differ significantly between the SBRT and VMAT arms. The first SAb value, however, was found to be significantly higher in the SBRT arm than in the VMAT arm ( vs ng/ml; ¼ 0.01). Evaluation of QOL and ISS Score Results Comparison of the mean scores of the SBRT and VMAT arms No significant difference was detected between the SBRT and VMAT arms in sexual activity and sexual functioning; urinary, incontinence, bowel, and hormonal symptoms; and ISS and ISS-O scores before RT, at RT completion, and 1.5, 4.5, 7.5, 10.5, and 13.5 months after RT (Table 2). Changes over time relative to baseline scores in SBRT and VMAT arms In both the SBRT and VMAT arms, sexual activity scores at 10.5 months ( ¼ and ¼ 0.028) and 13.5 months ( ¼ 0.01 and ¼ 0.008) showed a significant decrease compared with baseline scores. A significant decrease in sexual functioning score was detected at 13.5 months ( ¼ 0.02) in the SBRT arm and at 10.5 months ( ¼ 0.046) and 13.5 months ( ¼ 0.016) in the VMAT arm compared with baseline scores. No significant difference was found in urinary, incontinence, bowel, and hormonal symptom scores at the end of RT and during follow-ups compared with pre-rt scores in either the SBRT arm or the VMAT arm. Nevertheless, bowel ( ¼ 0.04) and hormonal ( ¼ 0.03) symptom scores at 13.5 months were significantly lower than baseline scores in the VMAT arm (Table 3). The ISS and ISS-O scores were significantly lower at 4.5 months ( ¼ and ¼ 0.02) and 7.5 months ( ¼ 0.02 and Comparison of SBRT and VMAT arms in terms of amount of changes over time relative to baseline scores The amount of change in sexual activity and sexual functioning; urinary, incontinence, and bowel symptoms; ISS and ISS-O scores during follow-ups after RT from baseline scores did not differ significantly between the SBRT and VMAT arms. The magnitude of increase in ISS scores, however, compared with baseline scores was significantly higher in the VMAT arm than in the SBRT arm ( ¼ 0.046) at the completion of RT. In addition, the decrease in hormonal symptom scores at 4.5 months ( ¼ 0.007), 10.5 months ( ¼ 0.027), and 13.5 months ( ¼ 0.021) from baseline scores was significantly higher in the VMAT arm than in the SBRT arm (Table 4). Toxicity Evaluation The SBRT and VMAT arms showed no significant difference regarding pretreatment transurethral resection of the prostate (TUR) incidence (17.9% vs. 20%; ¼ 0.8), the complication rate due to fiducial insertion (3.6% vs. 5%; ¼ 0.999), incidence of TUR or catheter requirement after RT (17.9% vs. 5%; ¼ 0.1), and rate of incontinence development after RT (7.1% vs. 5%; ¼ 0.999). Genitourinary system toxicities The incidence of genitourinary system (GUS) adverse effects according to grades in the SBRT and VMAT arms is presented in detail in Table 5. The presence of GUS toxicity during RT and during follow-ups was observed to be similar in the SBRT and VMAT arms, but the incidence of GUS toxicity at 4.5 months was found to be significantly higher in the SBRT arm than in the VMAT arm (50% vs. 30%; ¼ 0.03). No significant difference was detected between the SBRT and VMAT arms concerning the incidence of grade 2 or higher GUS toxicity during RT or during follow-ups. Gastrointestinal system toxicities Grade 3 gastrointestinal system (GIS) toxicity was not observed in either arm. Neither did the incidence of GIS toxicity presence nor grade 2 GIS toxicity rates during RT and during follow-ups differ significantly between the SBRT and VMAT arms. Discussion Several studies have established various questionnaires for patient self-assessment to investigate morbidity in detail. Repetitive assessments may provide more useful information in understanding long-term adverse effects and their changes over time instead of peak scores [12 14]. To succeed in these goals, 28 patients treated with SBRT and 20 patients who received VMAT (N ¼ 48) were included in our study and monitored regularly. In addition, of these 48 patients, 20 in the SBRT arm and 20 in the VMAT arm were evaluated in terms of QOL and detailed toxicity analysis using the EORTC QLQ-R25 module and ISS forms at baseline, RT completion, and during follow-ups. First, SA kinetics in our study were consistent with those in the literature[15]. The SA decline rate was significantly slower in the SBRT arm than in the VMAT arm, whereas SAn values were similar between the two groups. In addition, the magnitude of the first SAb was significantly higher in the SBRT group than in
5 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) Table 2 Comparison of SBRT and VMAT groups in terms of mean EORTC QLQ-R25 functioning (sexual activity and sexual functioning) and symptom (urinary, incontinence aid, bowel, and hormonal) scores and ISS and ISS-O scores. Time (mo) Sexual activity functioning scores Sexual functioning scores Baseline (100) (83) (46) (50) 0.79 RT completion (92) (100) (42) (67) (67) (75) (50) (28) (67) (67) (42) (25) (67) (67) (46) (25) (50) (33) (29) (21) (50) (17) (25) (0) 0.50 Urinary symptoms scores Incontinence aid scores Baseline (15) (27) (0) (0) 0.99 RT completion (19) (35) (0) (0) (19) (19) (0) (0) (15) (19) (0) (0) (13) (17) (0) (0) (17) (25) (0) (0) (15) (21) (0) (0) 0.17 Bowel symptom scores Hormonal symptom scores Baseline (8) (21) (11) (22) 0.09 RT completion (13) (13) (14) (17) (17) (17) (17) (17) (8) (13) (19) (6) (8) (8) (19) (14) (8) (4) (17) (8) (8) (0) (17) (6) 0.13 ISS scores ISS obstruction scores Baseline (8) (10) (4) (6) 0.95 RT completion (10) (13) (6) (6) (10) (8) (4) (4) (5) (8) (2) (3) (4) (8) (1) (3) (7) (8) (2) (3) (5) (8) (2) (2) 0.77 Note. Mann-Whitney U test/wilcoxon test. EORTC QLQ-R25, Quality of Life Questionnaire rostate Cancer Module; ISS, International rostate Symptom Score; ISS-O, ISS obstruction; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy. the VMAT group. Furthermore, repetitive SAb was observed in our study and other previous studies [16]. In a recently published study that included patients treated with brachytherapy (n ¼ 230), conventional RT (76 Gy/38 fr, n ¼ 58), or hypofractionated RT (45 Gy/9 fr, n ¼ 74), no significant difference was observed between the different modalities in terms of SAb. The authors concluded that SAb might be caused by the late RT damage to the healthy prostate tissue because the SAb was more common among patients with lower risk and fewer positive biopsies [17]. The median SAn values reported in the studies ranged between 0.1 and 1.6 ng/ml, which is consistent with our results [18]. After a rapid decline in SA following RT, SA values continue to decline slowly accompanied by SAb fluctuations, whereas lower SA nadir values are observed with longer follow-ups. Therefore, the decision for biopsy should not be taken immediately after RT in patients with an increase in SA; a benign SA bounce should be excluded by monitoring SA kinetics. When evaluating treatment complications, an infection that was treated with antibiotics developed in one patient in each group after fiducial insertion, and these patients completed RT without any problems. The infection incidence due to fiducial insertion was reported at about 7.7%, where one-third was in the form of urosepsis [19]. Concerning GIS toxicities, no grade 3 adverse effects or differences between the SBRT and VMAT arms were observed in the present study. The frequency of late grade 3 GIS or GUS toxicities was reported as 1% to 3% in SBRT studies [10]. Likewise, the two arms were similar in terms of grades 1 to 2 GUS toxicities in which adverse effects were prominent during the acute period after RT, and improved during follow-up. The most frequent GUS complication was urinary obstruction, which required TUR [20]. A grade 3 urinary retention due to an obstruction developed at 7.5 months and continued at 13.5 months in the SBRT arm. The group of patients with a history of TUR mostly constituted those with grade 3 toxicity. Catheter placement or TUR was needed in all of the five patients with a history of TUR in the SBRT arm and one of the four patients in the VMAT arm. TUR history has been reported as an obvious risk factor for late GUS toxicity in patients treated with SBRT [21]. In addition, Yu et al. [22] reported that GUS toxicities were significantly higher in the SBRT arm than in the IMRT arm at 24 months post-treatment, and toxicities were mainly in the form of urethritis, stricture, urinary incontinence, and/or obstruction (43.9%
6 96 Table 3 Changes over time relative to baseline EORTC QLQ-R25 functioning (sexual activity and sexual functioning) and symptom (urinary, incontinence aid, bowel, and hormonal) scores and ISS and ISS-O scores in SBRT and VMAT arms. Time (mo) Sexual activity functioning scores Sexual functioning scores RT completion 3 29 (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) ( 4) (0) (0) (0) ( 17) ( 33) (0) ( 25) ( 17) ( 25) ( 17) ( 17) ( 21) Urinary symptoms scores Incontinence aid scores RT completion ( 2) (0) (0) (0) (0) ( 4) (0) (0) ( 4) ( 6) (0) (0) ( 4) ( 2) (0) (0) ( 2) (0) (0) (0) ( 4) (0) (0) (0) 0.33 Bowel symptom scores Hormonal symptom scores RT completion (0) (0) (6) (0) (0) (0) (6) (0) (0) (0) (8) (0) (0) (0) (8) (0) (0) (0) (8) ( 3) (0) (0) (3) ( 6) 0.03 ISS scores ISS obstruction scores RT completion 0.1 7( 1) (2.5) (0) (0) ( 1) (0) ( 1) (0) ( 2) ( 2) ( 2) ( 1) ( 2) ( 1) ( 1) ( 1) ( 2) ( 2) ( 1) ( 1) ( 1) ( 3) ( 1) ( 2) VALUE IN HEALTH REGIONAL ISSUES 10C (2016) EORTC QLQ-R25, Quality of Life Questionnaire rostate Cancer Module; ISS, International rostate Symptom Score; ISS-O, ISS obstruction; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy.
7 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) Table 4 Comparison of SBRT and VMAT arms in terms of amount of changes over time relative to baseline EORTC QLQ-R25 functioning (sexual activity and sexual functioning) and symptom (urinary, incontinence aid, bowel, and hormonal) scores and ISS and ISS-O scores. Time (mo) Sexual activity functioning scores Sexual functioning scores RT completion 3 29 (0) (0) (0) (0) (0) 5 41 (0) (0) (0) (0) (0) (0) ( 4) (0) (0) (0) ( 17) ( 33) (0) ( 25) ( 17) ( 25) ( 17) ( 17) ( 21) 0.66 Urinary symptoms scores Incontinence aid scores RT completion ( 2) (0) (0) (0) (0) ( 4) (0) (0) ( 4) ( 6) (0) (0) ( 4) ( 2) (0) (0) ( 2) (0) (0) (0) ( 4) (0) (0) (0) 0.26 Bowel symptom scores Hormonal symptom scores RT completion (0) (0) (6) (0) (0) (0) (6) (0) (0) (0) (8) (0) (0) (0) (8) (0) (0) (0) (8) ( 3) (0) (0) (3) ( 6) ISS scores ISS obstruction scores RT completion 0.1 7( 1) (2.5) (0) (0) ( 1) (0) ( 1) (0) ( 2) 2.0 4( 2) ( 2) 1.5 3( 1) ( 2) 1.4 5( 1) ( 1) 1.5 4( 1) ( 2) 0.6 8( 2) ( 1) 0.9 6( 1) ( 1) 2.4 5( 3) ( 1) 2.0 3( 2) 0.79 EORTC QLQ-R25, Quality of Life Questionnaire rostate Cancer Module; ISS, International rostate Symptom Score; ISS-O, ISS obstruction; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy. vs. 36.3%; ¼ 0.001). Furthermore, King et al. [23] detected that the incidence of late urethral stricture that required dilatation was 3.5% for SBRT, which was higher than that reported for IMRT (0.5%). In our study, repetitive TURs were required in 3 of 28 (10.7%) patients in the SBRT arm. To avoid such toxicities, attention should be paid to patient selection; SBRT should not be administered to patients with a history of TUR. A significant reduction in sexual activity scores from baseline was observed at 10.5 and 13.5 months in both groups, which is in agreement with previous studies that reported that sexual dysfunction was a late-emerging adverse effect [24]. In a multicenter cohort study with 864 patients who underwent SBRT, urinary and bowel scores were found to decline in the first 3 months and returned to the initial values up to 6 months later, whereas sexual QOL was detected to have deteriorated, independent of ADT or age during the first 9 months [23]. In our study, no significant difference was observed in terms of urinary, incontinence, bowel, and hormonal symptom scores between the two groups. This is consistent with the study by Evans et al. [25], which compared IMRT, brachytherapy, or SBRT regarding QOL. The authors established that the three modalities were substantially similar to each other regarding QOL. In our study, ISS scores were found to increase during the early period following RT and significantly declined after 1 year, which is also congruous with other studies[26]. The ISS scores, however, decreased significantly at 1.5 and 4.5 months and then increased at 10.5 and 13.5 months from baseline in the SBRT arm. Similarly, ISS-O scores increased during the late period. These findings are consistent with previous reports that detected an increase in late urinary toxicities in patients treated with SBRT [27]. Conclusions It was found that both SBRT and VMAT treatments were effective options for localized prostate cancer. Grade 3 GUS toxicities were mainly observed in patients with a history of TUR in the SBRT arm. Deterioration was detected in sexual activity and sexual functioning QOL as a late toxicity in both arms. Acute hormonal and bowel symptoms were resolved in patients who received VMAT during follow-up. Although acute urinary symptoms were found to increase in the VMAT arm, late urinary toxicities were more common in patients who underwent SBRT. It may be concluded that both treatment modalities had similar effectiveness and provided acceptable outcomes in terms of toxicity and QOL. Acknowledgment We thank Mr David Chapman, who is a native-english speaker with scientific expertise, for language editing of the article.
8 98 Table 5 Genitourinary and gastrointestinal system toxicities according to CTCAE version 4 (grades in SBRT and VMAT groups). VMAT (%) SBRT (%) Toxicity Grade RT 1.5 mo 4.5 mo 7.5 mo 10.5 mo 13.5 mo RT 1.5 mo 4.5 mo 7.5 mo 10.5 mo 13.5 mo Genitourinary system toxicities ollakuria Nocturia Mean Min Max Incontinence Retention Obstruction Dysuria Urgency Gastrointestinal system toxicities roctitis Bleeding VALUE IN HEALTH REGIONAL ISSUES 10C (2016) CTCAE, Common Terminology Criteria for Adverse Events; Max., maximum; Min., minimum; RT, radiotherapy; SBRT, stereotactic body radiotherapy; VMAT, volumetric arc therapy.
9 VALUE IN HEALTH REGIONAL ISSUES 10C (2016) REFERENCES [1] Siegel R, Ma J, Zou Z, et al. Cancer statistics, CA Cancer J Clin 2014;64:9 29. [2] Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol hys 2009;74: [3] Diez, Vogelius IS, Bentzen SM. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol hys 2010;77: [4] Beckendorf V, Guerif S, Le rise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol hys 2011;80: [5] Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-igrt for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol hys 2012;84: [6] Vora SA, Wong WW, Schild SE, et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol 2013;190: [7] Hall WA, Colbert L, Nickleach D, et al. Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate. ract Radiat Oncol 2013;3:e [8] Mellon EA, Javedan K, Strom TJ, et al. A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer. ract Radiat Oncol 2015;5:11 5. [9] Hall WA, Fox TH, Jiang X, et al. Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer. J Am Coll Radiol 2013;10: [10] King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol hys 2013;87: [11] van Andel G, Bottomley A, Fossa SD, et al. An international field study of the EORTC QLQ-R25: a questionnaire for assessing the healthrelated quality of life of patients with prostate cancer. Eur J Cancer 2008;44: [12] Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol hys 1997;37:3 11. [13] Michalski JM, Winter K, urdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol hys 2005;62: [14] Smeenk RJ, Hoffmann AL, Hopman W, et al. Dose-effect relationships for individual pelvic floor muscles and anorectal complaints after prostate radiotherapy. Int J Radiat Oncol Biol hys 2012;83: [15] Kole T, Chen LN, Obayomi-Davies O, et al. rostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer. Acta Oncol 2015;54: [16] Sheinbein C, Teh BS, Mai WY, et al. rostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer. Urology 2010;76: [17] Waters A, Delouya G, Donath D, et al. Risk factors for SA bounce following radiotherapy: outcomes from a multi-modal therapy analysis. Can J Urol 2014;21: [18] Seisen T, Drouin SJ, he V, et al. Current role of image-guided robotic radiosurgery (Cyberknifes) for prostate cancer treatment. BJU Int 2013;111: [19] Loh J, Baker K, Sridharan S, et al. Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? Radiat Oncol 2015;10:38. [20] McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012;118: [21] eeters ST, Heemsbergen WD, van utten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol hys 2005;61: [22] Yu JB, Cramer LD, Herrin J, et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 2014;32: [23] King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol hys 2012;82: [24] Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of highdose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117: [25] Evans JR, Zhao S, Daignault S, et al. atient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015;116: [26] Eade TN, Guo L, Forde E, et al. Image-guided dose-escalated intensitymodulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy. BJU Int 2012;109: [27] Chen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013;8:58.
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More informationCyberKnife SBRT for Prostate Cancer
CyberKnife SBRT for Prostate Cancer Robert Meier, MD Swedish Radiosurgery Center Swedish Cancer Institute Seattle, WA 2017 ESTRO Meeting, Vienna Austria 5-year safety, efficacy & quality of life outcomes
More informationPACE Study. Hypofractionation 17/12/2014. Traditional Model of Fractionation 200 Response. What s the fraction sensitivity of prostate cancer?
0 0 17/12/2014 2 Outline of today s talk PACE Study Background rationale for PACE? Dr Nicholas van As A bit about technology. What is PACE? How can I get involved? London: 1 December 2014 250 Hypofractionation
More informationTechnological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review
Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Jayatissa R.M.G.C.S.B. (B.Sc.) Department of Radiography/Radiotherapy, Faculty of Allied Health
More informationLinac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery
Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico
More informationSection: Therapy Effective Date: October 15, 2016 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2016 Page: 1 of 10 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
More informationProstate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT)
Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT) The Institute for Clinical and Economic Review (ICER) has published appraisals on multiple management options for clinically-localized,
More informationExternal Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical
More informationAcute toxicity profile in prostate cancer with conventional and hypofractionated treatment
Viani et al. Radiation Oncology 2013, 8:94 RESEARCH Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment Open Access Gustavo Arruda Viani 1,3*, Lucas Bernardes Godoy
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationCYBERKNIFE SBRT FOR THE TREATMENT OF PROSTATE CANCER: 5 VS. 44 FRACTIONS THE PHILADELPHIA CYBERKNIFE CENTER EXPERIENCE
CYBERKNIFE SBRT FOR THE TREATMENT OF PROSTATE CANCER: 5 VS. 44 FRACTIONS THE PHILADELPHIA CYBERKNIFE CENTER EXPERIENCE Olusola Obayomi-Davies M.D. Philadelphia CyberKnife Center September 26 th, 2017 Disclosure
More informationPhase II study of FFF-SBRT in 5 fractions for low and intermediate risk prostate cancer
Phase II study of FFF-SBRT in 5 fractions for low and intermediate risk prostate cancer Ciro Franzese, G D Agostino, E Clerici, E Villa, A Tozzi, T Comito, C Iftode, AM Ascolese, F De Rose, S Pentimalli,
More informationStereotactic ablative body radiation for prostate cancer SABR
Stereotactic ablative body radiation for prostate cancer SABR John Armstrong. Sinead Callinan. Luke Rock. Beacon Hospital, Dublin, Ireland Low- Intermediate Risk Prostate Comparing treatment choices IMRT
More informationIntensity Modulated Radiotherapy (IMRT) of the Prostate
Medical Policy Manual Medicine, Policy No. 137 Intensity Modulated Radiotherapy (IMRT) of the Prostate Next Review: August 2018 Last Review: November 2017 Effective: December 1, 2017 IMPORTANT REMINDER
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More informationInnovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica
Innovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica 2014 HYPOFRACTIONATION & PROSTATE CANCER HYPOFRACTIONATION & PROSTATE CANCER: TECHNOLOGY: HIGH CONFORMAL DOSE & IMAGING
More informationVaginal Sparing with Volumetric Modulated Arc Therapy (VMAT) for Rectal Cancer. Scott Boulet BSc, RT(T)
Vaginal Sparing with Volumetric Modulated Arc Therapy (VMAT) for Rectal Cancer Scott Boulet BSc, RT(T) Outline Background Objectives Design Results Discussion Conclusion Acknowledgements Questions Background
More informationStereotactic Ablative Radiotherapy for Prostate Cancer
Stereotactic Ablative Radiotherapy for Prostate Cancer Laurie Cuttino, MD Associate Professor of Radiation Oncology VCU Massey Cancer Center Director of Radiation Oncology Sarah Cannon Cancer Center at
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationPROSTATE CANCER TREATMENT
PROSTATE CANCER TREATMENT INFORMATION GUIDE Several effective treatment options exist today for men diagnosed with prostate cancer. Each man s particular cancer, overall health, age, and lifestyle will
More informationBiodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy
More informationProstate SBRT Heterogeneous Dose Distribution: Rationale, Methods, Outcomes and Future Direction: 2017 Update
Prostate SBRT Heterogeneous Dose Distribution: Rationale, Methods, Outcomes and Future Direction: 2017 Update DONALD B. FULLER, M.D. RADIATION ONCOLOGIST GENESIS HEALTHCARE Disclosure & Disclaimer The
More informationResearch Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant
Radiotherapy, Article ID 130652, 6 pages http://dx.doi.org/10.1155/2014/130652 Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103
More information1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT
Donald B. Fuller, M.D. 1, John Naitoh, M.D. 2, Mark Reilly, M.D. 3, Chad Lee, Ph.D 1. 1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT Typically,
More informationFeasibility of the partial-single arc technique in RapidArc planning for prostate cancer treatment
Chinese Journal of Cancer Original Article Feasibility of the partial-single arc technique in RapidArc planning for prostate cancer treatment Suresh Rana 1 and ChihYao Cheng 2 Abstract The volumetric modulated
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationClinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate
Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical
More informationJean Pouliot, PhD Professor and Vice Chair, Department of Radiation Oncology, Director of Physics Division
IMRT / Tomo / VMAT / Cyberknife / HDR Brachytherapy: Jean Pouliot, PhD Professor and Vice Chair, Department of Radiation Oncology, Director of Physics Division Should Choices be Based on Dosimetric and
More informationAn Update on Radiation Therapy for Prostate Cancer
An Update on Radiation Therapy for Prostate Cancer David C. Beyer, MD, FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Objectives Review significant new data Identify leading trends in PCa
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer overview Prostate cancer is the most common form of cancer in American men, most prevalent in men over age 65 and fairly common in men 50-64
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationMaurizio Valeriani, Stefano Bracci *, Mattia Falchetto Osti, Teresa Falco, Linda Agolli, Vitaliana De Sanctis and Riccardo Maurizi Enrici
Valeriani et al. Radiation Oncology 2013, 8:137 RESEARCH Open Access Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or
More informationProstate Cancer. What is prostate cancer?
Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific
More informationTreatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience
Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience Scott Quarrier, 1 Aaron Katz, 2 Jonathan Haas 3 Abstract
More informationThree-year outcomes of 324 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and intensity modulated radiation therapy
Original Article Three-year outcomes of 324 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and intensity modulated radiation therapy Jekwon Yeh, Brandon Lehrich, Albert
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationBiodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy
More informationOPTIMIZATION OF COLLIMATOR PARAMETERS TO REDUCE RECTAL DOSE IN INTENSITY-MODULATED PROSTATE TREATMENT PLANNING
Medical Dosimetry, Vol. 30, No. 4, pp. 205-212, 2005 Copyright 2005 American Association of Medical Dosimetrists Printed in the USA. All rights reserved 0958-3947/05/$ see front matter doi:10.1016/j.meddos.2005.06.002
More informationCurrent and Emerging Standards in Radiation Therapy for Prostate Cancer
Current and Emerging Standards in Radiation Therapy for Prostate Cancer Amandeep R. Mahal, BS, and James B. Yu, MD, MHS Abstract Improved radiation technology has allowed physicians to precisely target
More informationDescription. Section: Therapy Effective Date: October 15, 2015 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2015 Page: 1 of 14 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationAdjuvant and Salvage Radiation for Prostate Cancer. Savita Dandapani, MD, PhD
Adjuvant and Salvage Radiation for Prostate Cancer Savita Dandapani, MD, PhD DISCLOSURES I am a consultant for Reflexion, receive funding from Bayer, and on the Speaker s Bureau with Astra Zeneca. Post-prostatectomy
More informationBRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital
BRACHYTHERAPY FOR PROSTATE CANCER Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital PROSTATE BRACHYTHERAPY Why brachytherapy? How do we do it? What are the results? Questions?
More informationUniversity of California, Los Angeles, Los Angeles, CA, 2 FROS Radiation Oncology and CyberKnife Center, Flushing, NY, 3
Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study A. U. Kishan 1, A. Katz 2, C. A. Mantz 3, F. I.
More informationLinac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR
Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,
More informationTRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY
TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 1 TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY BRENDAN CAREY, MD TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 2 TRANSRECTAL ULTRASOUND-GUIDED
More informationGuidelines for the use of inversely planned treatment techniques in Clinical Trials: IMRT, VMAT, TomoTherapy
Guidelines for the use of inversely planned treatment techniques in Clinical Trials: IMRT, VMAT, TomoTherapy VERSION 2.1 April 2015 Table of Contents Abbreviations & Glossary... 3 Executive Summary...
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationProspective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer
Sveistrup et al. Radiation Oncology (2016) 11:117 DOI 10.1186/s13014-016-0689-4 RESEARCH Open Access Prospective assessment of the quality of life before, during and after image guided intensity modulated
More informationDoes RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
More informationA treatment planning study comparing Elekta VMAT and fixed field IMRT using the varian treatment planning system eclipse
Peters et al. Radiation Oncology 2014, 9:153 RESEARCH Open Access A treatment planning study comparing Elekta VMAT and fixed field IMRT using the varian treatment planning system eclipse Samuel Peters
More informationCLINICAL WORKSHOP IMAGE-GUIDED HDR BRACHYTHERAPY OF PROSTATE CANCER
CLINICAL WORKSHOP IMAGE-GUIDED HDR BRACHYTHERAPY OF PROSTATE CANCER Klinikum Offenbach Nucletron April 27 th 28 th, 2014 History HDR Protocols for Boost and Monotherapy, Results, Logistics and Practical
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationA Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer
A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer Tony Kin Ming Lam Radiation Planner Dr Patricia Lindsay, Radiation Physicist Dr John Kim, Radiation Oncologist Dr Kim Ann Ung,
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationThe role of Radiation Oncologist: Hi-tech treatments for liver metastases
The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The
More informationDosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer
Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research
More informationMedical Policy. MP High-Dose Rate Temporary Prostate Brachytherapy
Medical Policy MP 8.01.33 BCBSA Ref. Policy: 8.01.33 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.79 Cryoablation of Prostate Cancer 8.01.10 Charged-Particle
More informationPROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College
PROSTATE CANCER BRACHYTHERAPY Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College Risk categorization Very Low Risk Low Risk Intermediate Risk High Risk
More informationA TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM *
Romanian Reports in Physics, Vol. 66, No. 2, P. 394 400, 2014 A TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM * D. ADAM 1,2,
More informationCorporate Medical Policy
Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate
More informationA PRACTICAL METHOD TO ACHIEVE PROSTATE GLAND IMMOBILIZATION AND TARGET VERIFICATION FOR DAILY TREATMENT
PII S0360-3016(01)02663-3 Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 5, pp. 1431 1436, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationHDR vs. LDR Is One Better Than The Other?
HDR vs. LDR Is One Better Than The Other? Daniel Fernandez, MD, PhD 11/3/2017 New Frontiers in Urologic Oncology Learning Objectives Indications for prostate brachytherapy Identify pros/cons of HDR vs
More informationRadiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
More informationThe Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre
The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation Roberto Alonzi Mount Vernon Cancer Centre Overview Introduction and rationale for focused dose escalation
More informationFROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017
FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips
More informationDosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer
Received: 31 October 2016 Revised: 24 January 2017 Accepted: 7 February 2017 DOI: 10.1002/acm2.12063 RADIATION ONCOLOGY PHYSICS Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body
More informationProstate Cancer. What is prostate cancer?
Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum, below the bladder and above the base of the penis. Your doctor may perform
More informationEmbracing Technology & Timing of Salvage Hormones
Embracing Technology & Timing of Salvage Hormones Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology Sunnybrook Health Sciences Centre University of Toronto Us Too, Brampton October
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationIntensity-Modulated Radiotherapy (IMRT) of the Prostate
Intensity-Modulated Radiotherapy (IMRT) of the Prostate Policy Number: 8.01.47 Last Review: 5/2018 Origination: 5/2009 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationThe use of SpaceOAR hydrogel in dose-escalated prostate cancer radiotherapy and its impact on rectal dosimetry
The use of SpaceOAR hydrogel in dose-escalated prostate cancer radiotherapy and its impact on rectal dosimetry Poster No.: R-0296 Congress: Type: Authors: Keywords: DOI: 2014 CSM Scientific Exhibit F.
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More informationRadiation Therapy: From Fallacy to Science
27 th Annual Management of Colon and Rectal Diseases 2.23.2019 Radiation Therapy: From Fallacy to Science Hadi Zahra, MD, DABR Radiation Oncologist CHI Health Henry Lynch Cancer Center Assistant Clinical
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationHigh-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date
MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationFuture Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center
Future Directions in Prostate Cancer: The Case for Protons John J. Coen, MD Helen & Harry Gray Cancer Center November 14, 2012 Protons and prostate cancer Early proton experience at the MGH The case for
More informationPropensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer
J Radiat Oncol (2016) 5:187 195 DOI 10.1007/s13566-015-0237-0 ORIGINAL RESEARCH Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer Caspian Oliai 1 &
More informationNew Radiation Treatment Modalities in the Treatment of Lung Cancer
New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions
More informationDose escalation with external beam therapy for
Rapid Communication Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationTreatment of exceptionally large prostate cancer patients with low-energy intensity-modulated photons
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 7, NUMBER 4, FALL 2006 Treatment of exceptionally large prostate cancer patients with low-energy intensity-modulated photons Mei Sun and Lijun Ma a University
More informationAdvances in radiotherapy technology for prostate cancer: What every GP should know
CLINICAL Advances in radiotherapy technology for prostate cancer: What every GP should know Peter Gorayski, Mark B Pinkham, Margot Lehman Background One in five Australian men are diagnosed with prostate
More informationCyberKnife Radiotherapy For Localized Prostate Cancer: Rationale And Technical Feasibility
Open Access Article The authors, the publisher, and the right holders grant the right to use, reproduce, and disseminate the work in digital form to all users. Technology in Cancer Research & Treatment
More informationTrina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April
Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and
More informationComputed tomography based evaluation of prostatic fiducial marker migration between the periods of insertion and simulation
Turk J Urol 2017; 43(4): 451-5 DOI: 10.5152/tud.2017.29726 UROONCOLOGY Original Article 451 Computed tomography based evaluation of prostatic fiducial marker migration between the periods of insertion
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationSome Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer
Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized
More informationPSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
More informationEvaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases
Evaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases CASE STUDY Institution: Odette Cancer Centre Location: Sunnybrook
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More informationBrachytherapy for Prostate Cancer
Brachytherapy for Prostate Cancer Who should be thinking about this and why... Juanita Crook Professor Radiation Oncology University of Toronto Princess Margaret Hospital Many options watchful waiting?
More information